-
1.发明授权
公开(公告)号：US4454161A
公开(公告)日：1984-06-12
申请号：US336941
申请日：1982-01-04
IPC分类号： A21D8/04 , A23C9/154 , A23G3/00 , A23G3/36 , A23L7/104 , A23L17/00 , A23L23/10 , C12N9/10 , A23L1/195 , A21D10/00 , C12Q1/48
摘要： The present invention relates to a process for the production of branching enzyme, and a method for improving the qualities of food products therewith. According to the present invention, a large amount of branching enzyme with a high specific activity can be easily obtained, and employment of the branching enzyme in food processing remarkably improves the qualities of food products without changing the desirable inherent properties of their amylaceous constituent(s); thus, said food products retain their qualities over a long period of time, prolonging extremely their shelf lives.
摘要翻译： 本发明涉及生产分支酶的方法，以及提高其食品质量的方法。 根据本发明，可以容易地获得大量比活性的分支酶，并且在食品加工中使用分支酶显着提高了食品的品质，而不改变其淀粉成分的理想固有性质 ）; 因此，食品长期保持品质，延长了保质期。
-
公开(公告)号：US4486417A
公开(公告)日：1984-12-04
申请号：US320745
申请日：1981-11-12
申请人： Kaname Sugimoto , Toshio Miyake
发明人： Kaname Sugimoto , Toshio Miyake
CPC分类号： A61K9/0029
摘要： A process for the production of an O/W emulsion for hyperalimentation comprising homogenization of a composition comprising hydrophobic substance, emulsifier, water and maltose into minute droplets of O/W emulsion. The emulsion can provide a higher caloric nutritive supplement to patients than conventional emulsions using glycerin. It is stable over a wide temperature range and it can be stored for long periods of time. The emulsion is particularly useful in emergency medical situations where enteral or parenteral hyperalimentation is required for the patient.
摘要翻译： 一种用于生产用于过度补液的O / W乳液的方法，包括将包含疏水物质，乳化剂，水和麦芽糖的组合物均匀化成微小的O / W乳液液滴。 使用甘油的乳液可以提供比常规乳液更高的热量营养补充剂。 它在很宽的温度范围内是稳定的，可以长时间储存。 该乳剂在患者需要肠内或肠胃外过度增生的紧急医疗情况下特别有用。
-
公开(公告)号：US4621053A
公开(公告)日：1986-11-04
申请号：US584017
申请日：1984-02-27
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： A61K35/12 , A61K38/00 , C07K14/575 , C07K14/59 , C07K14/61 , C07K14/62 , C12N5/16 , C12P21/00 , C12N15/00 , C12N5/00 , C12N5/02
CPC分类号： C12R1/91 , C07K14/57554 , C07K14/59 , C07K14/61 , C07K14/62 , C12N5/16 , A61K35/12 , A61K38/00 , Y10S435/948
摘要： Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, parathyroid hormone and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced.
摘要翻译： 人类肽激素例如胰岛素，生长激素，催乳素，促肾上腺皮质激素，胎盘激素，降钙素，甲状旁腺激素和促甲状腺激素是通过在非人类中植入能够产生人肽激素的人类人类杂交瘤淋巴样细胞系产生的 温血动物 一段时间后，将所得肿瘤提取并分解，然后在体外在适于累积人肽激素的条件下培养。 人类人类杂交瘤淋巴母细胞系优选通过将本体能够产生人类肽激素的亲本人类细胞与人淋巴母细胞系，优选来自白血病来源融合来形成。 该方法允许可以产生的人类肽激素的量的显着增加。
-
公开(公告)号：US4377513A
公开(公告)日：1983-03-22
申请号：US291848
申请日：1981-08-10
IPC分类号： A61K38/16 , A61K35/12 , A61K38/00 , A61K38/22 , C07K14/505 , C12N15/00 , A61K37/24 , C07G7/00
CPC分类号： C07K14/505 , A61K38/00 , Y10S435/848 , Y10S530/808 , Y10S530/809 , Y10S530/826 , Y10S530/828 , Y10S530/835 , Y10S530/837
摘要： The present invention relates to a process for the production of human erythropoietin.More precisely, the invention relates to a process for the mass production of human erythropoietin, comprising in vivo multiplication of human lymphoblastoid cells capable of producing human erythropoietin, and human erythropoietin production by the multiplied human lymphoblastoid cells.The human erythropoietin production according to the present invention is much higher, in terms of human erythropoietin production per cell, than that attained by conventional processes using in vitro tissue culture; thus, human erythropoietin can be used in a sufficient amount for the prevention and treatment of human diseases.
摘要翻译： 本发明涉及一种生产人促红细胞生成素的方法。 更确切地说，本发明涉及大规模生产人促红细胞生成素的方法，包括能够产生人促红细胞生成素的人类淋巴母细胞样细胞的体内增殖和由繁殖的人类淋巴母细胞细胞产生的促红细胞生成素。 根据本发明的人促红细胞生成素的生产比使用体外组织培养的常规方法获得的要高得多，就人细胞促红细胞生成素的产生而言， 因此，人类促红细胞生成素可以以足够的量用于预防和治疗人类疾病。
-
公开(公告)号：US4621051A
公开(公告)日：1986-11-04
申请号：US585618
申请日：1984-03-05
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： A61K38/00 , A61K35/12 , A61K38/16 , A61K38/22 , A61K38/28 , A61P43/00 , C12P1/00 , C12P21/00 , C12R1/91 , C12N15/00 , C12N5/00 , C12N5/02
CPC分类号： C12P1/00 , Y10S435/948
摘要： The present invention relates to a process for the production of human Multiplication-Stimulating Activity (hMSA).More precisely, the invention relates to a process for the mass production of low-cost hMSA, comprising in vivo multiplication of human cells capable of producing said substance, and subsequent in vitro production of hMSA with the multiplied human cells.hMSA production according to the present invention is much higher, about 2-50-fold higher in terms of hMSA production per cell, than that attained by conventional processes: thus, hMSA can be used in a sufficient amount in the prevention and treatment of human diseases.
摘要翻译： 本发明涉及一种生产人倍增刺激活性（hMSA）的方法。 更确切地说，本发明涉及大规模生产低成本hMSA的方法，包括能够产生所述物质的人类细胞的体内增殖，以及随后的繁殖的人细胞体外产生hMSA。 根据本发明的hMSA生产要高得多，比通过常规方法获得的hMSA生产高约2-50倍;因此，hMSA可以在预防和治疗人体中足够的量使用 疾病
-
公开(公告)号：US4537852A
公开(公告)日：1985-08-27
申请号：US320746
申请日：1981-11-12
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： C12N5/06 , C12N5/16 , C12N9/00 , C12N9/72 , C12N15/02 , C12N15/09 , C12N5/00 , C12N15/00 , C12R1/91
CPC分类号： C12N9/6462 , C12N5/163 , C12Y304/21073 , Y10S435/948
摘要： The present invention relates to a process for the production of human urokinase. More precisely, the present invention relates to a process for the mass production of human urokinase, comprising in vivo multiplication of human cells capable of producing human urokinase, using the nutrient body fluid of a non-human warm-blooded animal, and exposure of the multiplied human cells to an urokinase inducer. The human urokinase present production according to the invention is much higher than that attained by conventional methods; thus, human urokinase can be used in sufficient amount in the prevention and treatment of human diseases.
摘要翻译： 本发明涉及一种生产人尿激酶的方法。 更准确地说，本发明涉及大规模生产人尿激酶的方法，其包括使用非人温血动物的营养体液和能够产生人尿激酶的人细胞的体内增殖 将人细胞增殖到尿激酶诱导物。 根据本发明的人尿激酶存在的生产比通过常规方法获得的高得多; 因此，人尿激酶可以在预防和治疗人类疾病中足够使用。
-
公开(公告)号：US4328207A
公开(公告)日：1982-05-04
申请号：US107557
申请日：1979-12-27
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： C07K14/555 , A61K45/02 , A61K39/00
CPC分类号： C07K14/555 , Y10S435/811
摘要： The present invention relates to a process which is easily applicable for industrial production of mouse interferon.Particularly, the present invention relates to a process based on the discovery that a large amount and high activity of mouse interferon is obtained by transplanting established mouse tumor cells to other warm-blooded animal body or inoculating the cells in a culture medium charged in a filter-membrane-interposed diffusion chamber which is designed and fitted up to or in the animal body so that its nutrient body fluid feeds the cells, multiplying the transplanted or inoculated cells in the warm-blooded animal body or the diffusion chamber utilizing said body fluid, and exposing the multiplied cells to the action of interferon inducer in vitro or in vivo.
摘要翻译： 本发明涉及一种易于适用于小鼠干扰素工业化生产的方法。 特别地，本发明涉及一种基于以下发现的方法：通过将已建立的小鼠肿瘤细胞移植到其他温血动物身体或将细胞接种在装入过滤器的培养基中而获得大量和高活性的小鼠干扰素 - 设计并装配到动物体内的膜式扩散室，使得其营养体液供给细胞，使用所述体液将温血动物体或扩散室中的移植或接种细胞倍增， 并将经繁殖的细胞暴露于干扰素诱导物在体外或体内的作用。
-
公开(公告)号：US4621052A
公开(公告)日：1986-11-04
申请号：US619708
申请日：1984-06-14
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： C12P21/00 , A61K35/12 , A61K35/42 , A61K38/00 , C07K14/485 , C12P1/00 , C12R1/91 , C12N5/00 , C12N5/02 , C12N15/00
CPC分类号： C12R1/91 , C07K14/485 , A61K38/00 , Y10S435/948
摘要： The present invention relates to a process for the production of human epidermal growth factor (hEGF). More precisely, the present invention relates to a process for the mass production of hEGF, comprising in vivo or in vitro multiplication of human cells capable of producing hEGF, and in vitro cultivation of the multiplied human cells to produce hEGF. The hEGF production according to the present invention is much higher than that attained by conventional processes; thus, hEGF can be obtained in a sufficient amount for use in the prevention and treatment of human diseases.
摘要翻译： 本发明涉及一种生产人表皮生长因子（hEGF）的方法。 更准确地说，本发明涉及大量生产hEGF的方法，包括能够产生hEGF的人类细胞的体内或体外繁殖，以及繁殖的人细胞的体外培养以产生hEGF。 根据本发明的hEGF生产比通过常规方法获得的高得多; 因此，可以以足够的量获得用于预防和治疗人类疾病的hEGF。
-
公开(公告)号：US4621050A
公开(公告)日：1986-11-04
申请号：US585617
申请日：1984-03-05
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： C12N15/02 , A61K35/12 , A61K38/00 , A61K38/16 , A61P35/02 , A61P37/00 , C07K14/53 , C12N5/00 , C12N5/02 , C12N15/00 , C12P21/00
CPC分类号： C07K14/53 , Y10S435/948
摘要： A process for the mass production of hCSF, comprises cell fusion of human lymphoblastoid cells with any human cells capable of producing said substance, in vivo multiplication of the resultant hybridoma cells, using a non-human warm-blooded animal, and in vivo cultivation of the multiplied hybridoma cells to produce hCSF. The hCSF production according to the present process is much higher than that attained by conventional processes; thus, hCSF can be used in a sufficient amount in the prevention and treatment of human diseases.
摘要翻译： 大规模生产hCSF的方法包括人类淋巴母细胞细胞与能够产生所述物质的任何人类细胞的细胞融合，所得杂交瘤细胞的体内增殖，使用非人体温血动物，体内培养 繁殖杂交瘤细胞产生hCSF。 根据本方法的hCSF生产要比常规方法所得到的高得多; 因此，hCSF可以在预防和治疗人类疾病中足够的量使用。
-
公开(公告)号：US4383034A
公开(公告)日：1983-05-10
申请号：US290861
申请日：1981-08-07
申请人： Kaname Sugimoto
发明人： Kaname Sugimoto
IPC分类号： C12N15/02 , A61K35/28 , A61K35/30 , A61K38/00 , A61K38/24 , C07K14/435 , C07K14/59 , C12N5/06 , C12N15/00 , C12P21/00 , C12P21/02 , C12P21/04
摘要： The present invention relates to a process for the production of human follicle-stimulating hormone (hFSH).More precisely, the invention relates to a process for the mass production of hFSH, comprising in vivo multiplication of human cells capable of producing hFSH, and exposure of the multiplied human cells to a follicle-stimulating hormone inducer.The hFSH production according to the invention is much higher than that attained by conventional processes using in vitro tissue culture; thus, hFSH can be used in a sufficient amount in the prevention and treatment of human diseases.
摘要翻译： 本发明涉及一种生产人卵泡刺激素（hFSH）的方法。 更准确地说，本发明涉及大规模生产hFSH的方法，包括能够产生hFSH的人类细胞的体内增殖，以及将倍增的人细胞暴露于促卵泡激素诱导剂。 根据本发明的hFSH生产比使用体外组织培养的常规方法获得的高得多; 因此，hFSH可以用于预防和治疗人类疾病的足够量。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.026 秒)